A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 170 participants.
Also called NCT03449251
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT03449251
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03449251. Randomized; triple masking; primary purpose other. Start 2018-03-28 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
- Acronym
- DEFINE
- Condition
- Cardiovascular Diseases
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Apelin
- Intervention (Drug)
- Relaxin
- Intervention (Drug)
- Normal saline
- Intervention (Diagnostic test)
- Verapamil
- Intervention (Diagnostic test)
- LN Monomethyl arginine
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Collaborator
- University of Cambridge
- Collaborator
- AstraZeneca
- Collaborator
- MedImmune LLC
Record details
- Record id
cardio:ct-nct03449251- Content hash
a4947541b75e286aa2879dc4da79d070f35cdb880658031ba009b641d2bec19d